Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J, Factor SA, Balaguer E, Schwarz J, Chaudhuri KR, Isaacson SH, Wu S, Denecke Muhr C, Kulisevsky J. Kassubek J, et al. Among authors: balaguer e. J Neurol. 2024 Jun;271(6):3554-3570. doi: 10.1007/s00415-024-12323-2. Epub 2024 Mar 28. J Neurol. 2024. PMID: 38546829 Free PMC article. Clinical Trial.
Validation of the OPTIMIPARK Questionnaire: A Tool to Optimize Treatment in Parkinson's Disease.
Máñez-Miró JU, Vivancos-Matellano F, Alonso-Frech F, Vela-Desojo L, López-Ariztegui N, López-Manzanares L, Balaguer E, Martínez-Castrillo JC, Herrero-Infante Y, Gasca-Salas C, Morales-Casado MI, Casas E, Hernández A, Pareés I, Tegel-Ayuela I, Martínez-Fernández R, Martinez-Martin P. Máñez-Miró JU, et al. Among authors: balaguer e. Mov Disord Clin Pract. 2022 Oct 18;9(8):1085-1093. doi: 10.1002/mdc3.13581. eCollection 2022 Nov. Mov Disord Clin Pract. 2022. PMID: 36339297 Free PMC article.
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D; ALLAY-LID I and ALLAY-LID II study groups. Rascol O, et al. Parkinsonism Relat Disord. 2022 Mar;96:65-73. doi: 10.1016/j.parkreldis.2022.01.022. Epub 2022 Feb 8. Parkinsonism Relat Disord. 2022. PMID: 35227940 Free article. Clinical Trial.
Multicentre, randomised, single-blind, parallel group trial to compare the effectiveness of a Holter for Parkinson's symptoms against other clinical monitoring methods: study protocol.
Rodríguez-Molinero A, Hernández-Vara J, Miñarro A, Pérez-López C, Bayes-Rusiñol À, Martínez-Castrillo JC, Pérez-Martínez DA; Monitoring Parkinson’s patients Mobility for therapeutic purposes research group. Rodríguez-Molinero A, et al. BMJ Open. 2021 Jul 19;11(7):e045272. doi: 10.1136/bmjopen-2020-045272. BMJ Open. 2021. PMID: 34281918 Free PMC article.
Outpatient treatment engagement after suicidal attempt: A multisite prospective study.
Costemale-Lacoste JF, Balaguer E, Boniface B, Ivascu EB, Bernardini C, Metton JP, Bouhlal A, Ghanem T, Corruble E, Hardy P, Hozer F; DTRF Paris-Sud group. Costemale-Lacoste JF, et al. Among authors: balaguer e. Psychiatry Res. 2017 Dec;258:21-23. doi: 10.1016/j.psychres.2017.09.062. Epub 2017 Sep 25. Psychiatry Res. 2017. PMID: 28982037
Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.
Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group. Trenkwalder C, et al. Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19. Lancet Neurol. 2015. PMID: 26494524 Clinical Trial.
36 results